BioVenture VoiCes with Chris Garabedian Episode 4: Enavate Sciences’ Sara Nayeem
Oct 21, 2024
Sara Nayeem, a venture investor with ~16 years focused on therapeutics and rare disease, describes career turns from medicine to early-stage biotech investing. She talks about firm styles and timing for investments. Topics include rare disease evolution, regulatory and clinical trial challenges, accelerator models, and how Innovate/Ennovate approaches larger first checks into therapeutics.
AI Snips
Chapters
Transcript
Episode notes
From Med School To VC
- Sara Nayeem recounts her path from Harvard biology to Yale MD/MBA and Wall Street to venture capital.
- She decided to shift from clinical practice to the business side after an MBA internship at Merrill Lynch.
Volume Of Deals Trains Investors
- Large, established firms like NEA give junior investors broad deal exposure and many 'reps' across sectors.
- That volume of experience accelerates learning about what works in different therapeutic areas.
Big-Firm Strategy Is Partner-Driven
- Investment theses often reflect partner interests within large firms, creating a mosaic strategy rather than a single unified plan.
- NEA's healthcare portfolio blended rare disease, precision oncology, devices, and services driven by individual partner focus.